ReviewFrontiers in neurology2021
Microglia-Derived Interleukin 23: A Crucial Cytokine in Alzheimer's Disease?
Review in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer's Disease?Dermatology and therapy · 2026Review
- Immune-proteo-metabolomic changes link to Aβ and tau pathology in Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The IL-12 family cytokines in neurodegenerative diseases: dual roles in neurotoxicity and neuroprotection.Inflammopharmacology · 2025Review
- Mobile application leads to psychological improvement and correlated neuroimmune function change in subjective cognitive decline.NPJ digital medicine · 2025Article
- Brain interleukins and Alzheimer's disease.Metabolic brain disease · 2025Review
- Altered serum interleukin-17A and interleukin-23A levels may be associated with the pathophysiology and development of generalized anxiety disorder.Scientific reports · 2024Article
- Roles of Cytokines in Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Comprehensive Analysis of Lung Adenocarcinoma and Brain Metastasis through Integrated Single-Cell Transcriptomics.International journal of molecular sciences · 2024Article
- Molecular mechanisms of sulforaphane in Alzheimer's disease: insights from an in-silico study.In silico pharmacology · 2024Article
- IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.Frontiers in immunology · 2024Review
- Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges.International journal of molecular sciences · 2023Review
- Article
- Endothelial TFEB signaling-mediated autophagic disturbance initiates microglial activation and cognitive dysfunction.Autophagy · 2023Article
- The Central Nervous System Source Modulates Microglia Function and Morphology In Vitro.International journal of molecular sciences · 2023Article
- The homeostatic function of Regnase-2 restricts neuroinflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Alzheimer's disease biomarker profiling in a memory clinic cohort without common comorbidities.Brain communications · 2023Article
- The acute effects of antimicrobials and lipopolysaccharide on the cellular mechanisms associated with neurodegeneration in pubertal male and female CD1 mice.Brain, behavior, & immunity - health · 2022Article
- Bisdemethoxycurcumin (BDC)-Loaded H-Ferritin-Nanocages Mediate the Regulation of Inflammation in Alzheimer's Disease Patients.International journal of molecular sciences · 2022Article
- Neurological Complications of Biological Treatment of Psoriasis.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuronal cell death, amyloid β plaque formation and development of neurofibrillary tangles are among the characteristics of Alzheimer's disease (AD). In addition to neurodegeneration, inflammatory processes such as activation of microglia and astrocytes are crucial in the pathogenesis and progression of AD. Cytokines are essential immune mediators of the immune response in AD. Recent data suggest a role of interleukin 23 (IL-23) and its p40 subunit in the pathogenesis of AD and corresponding animal models, in particular concerning microglia activation and amyloid β plaque formation. Moreover, in animal models, the injection of anti-p40 antibodies resulted in reduced amyloid β plaque formation and improved cognitive performance. Here, we discuss the pathomechanism of IL-23 mediated inflammation and its role in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.